8-K Announcements
6Material company update
Mar 19, 2026·SEC
Material company update
Feb 23, 2026·SEC
Material company update
Dec 16, 2025·SEC
Inhibrx Biosciences, Inc.(INBX)Earnings, Financials & Key Ratios
INBX•NASDAQ
$141.84
$2.07B mkt cap·Price updated May 6, 2026
AboutInhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was incorporated in 2024 and is based in La Jolla, California.Show more
- Revenue$1M+550.0%
- EBITDA-$135M+59.0%
- Net Income-$140M-108.3%
- EPS (Diluted)-9.04-107.8%
- EBITDA Margin-10386.54%+93.7%
- Operating Margin-10386.54%+93.7%
- Net Margin-10773.46%-101.3%
- ROE-197.85%-110.4%
- Debt/Equity13.39+22122.2%
INBX Key Insights
Inhibrx Biosciences, Inc. (INBX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Excellent 3Y average ROE of 410.9%
- ✓Momentum leader: RS Rating 97 (top 3%)
- ✓Healthy 5Y average net margin of 162366.1%
✗Weaknesses
- ✗High debt to equity ratio of 13.4x
- ✗Weak Piotroski F-Score: 2/9
- ✗Negative free cash flow
- ✗Sales declining 36.7% over 5 years
- ✗Expensive at 274.8x book value
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
INBX Price & Volume
Inhibrx Biosciences, Inc. (INBX) stock price & volume — 10-year historical chart
Loading chart...
INBX Growth Metrics
Inhibrx Biosciences, Inc. (INBX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-36.72%
3 Years-15.98%
TTM550%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-108.3%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-107.67%
Return on Capital
10 Years-435.56%
5 Years-98.2%
3 Years-120.43%
Last Year-106.86%
INBX Recent Earnings
Inhibrx Biosciences, Inc. (INBX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 3/12 qtrs (25%)●Beat Revenue 2/12 qtrs (67%)
Q2 2026Latest
Mar 19, 2026EPS
$2.11
Est $2.08
-1.4%
Revenue
—
Est $1M
Q4 2025
Nov 14, 2025EPS
$2.28
Est $2.08
-9.6%
Revenue
—
Q3 2025
Aug 13, 2025EPS
$1.85
Est $2.92
+36.6%
Revenue
$1M
Q2 2025
May 14, 2025EPS
$2.80
Est $2.55
-9.8%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 19, 2026 | $2.11vs $2.08-1.4% | —vs $1M |
| Q4 2025 | Nov 14, 2025 | $2.28vs $2.08-9.6% | — |
| Q3 2025 | Aug 13, 2025 | $1.85vs $2.92+36.6% | $1M |
| Q2 2025 | May 14, 2025 | $2.80vs $2.55-9.8% | — |
Based on last 12 quarters of dataView full earnings history →
INBX Peer Comparison
Inhibrx Biosciences, Inc. (INBX) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 IMVT | 5.83B | 28.67 | -10.50 | -47.07% | 0.00 | |||
 ARQT | 3.02B | 24.17 | -185.92 | 91.34% | -0.57% | -1.41% | 0.03 | |
 KYMR | 7.04B | 86.26 | -23.38 | -16.72% | -6.12% | -25.02% | 0.05 | |
 PRAX | 7.61B | 337.95 | -25.07 | -100% | -58.74% | 0.00 | ||
 TGTX | 6.7B | 41.97 | 15.15 | 87.32% | 65.95% | 87.36% | 0.40 | |
 RCUS | 2.62B | 26.00 | -7.90 | -4.26% | -156.36% | -68.97% | 0.16 | |
 ALKS | 5.89B | 35.32 | 24.70 | -5.25% | 9.78% | 8.82% | 0.04 | |
 XNCR | 954.14M | 13.01 | -10.49 | 13.65% | -185.71% | -23.68% | 0.30 |
Compare INBX vs Peers
Inhibrx Biosciences, Inc. (INBX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
INBX Income Statement
Inhibrx Biosciences, Inc. (INBX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 7.95M | 7.5M | 9.09M | 12.81M | 7.13M | 2.19M | 1.8M | 200K | 1.3M |
| Revenue Growth % | 19.24% | -5.66% | 21.24% | 40.86% | -44.37% | -69.24% | -17.88% | -88.89% | 550% |
| Cost of Goods Sold | 25.51M | 33.45M | 47.91M | 73.5M | 2.69M | 110.19M | 1.19M | 2.29M | 0 |
| COGS % of Revenue | 320.88% | 446.05% | 526.86% | 573.82% | 37.73% | 5026.73% | 66.17% | 1142.5% | - |
| Gross Profit | -17.56M▲ 0% | -25.95M▼ 47.8% | -38.81M▼ 49.5% | -60.69M▼ 56.4% | 4.44M▲ 107.3% | -107.99M▼ 2533.9% | 609K▲ 100.6% | -2.08M▼ 442.4% | 0▲ 100.0% |
| Gross Margin % | -220.88% | -346.05% | -426.86% | -473.82% | 62.27% | -4926.73% | 33.83% | -1042.5% | - |
| Gross Profit Growth % | -70.07% | -47.8% | -49.55% | -56.35% | 107.31% | -2533.94% | 100.56% | -442.36% | 100% |
| Operating Expenses | 27.68M | 37.01M | 52.81M | 80.25M | 12.34M | 21.12M | 219.83M | 329.36M | 136.32M |
| OpEx % of Revenue | 348.15% | 493.51% | 580.74% | 626.57% | 173.21% | 963.59% | 12212.78% | 164681.5% | 10486.54% |
| Selling, General & Admin | 2.61M | 4.65M | 9.02M | 6.84M | 12.36M | 21.12M | 29.38M | 127.91M | 23.3M |
| SG&A % of Revenue | 32.82% | 62.05% | 99.18% | 53.37% | 173.4% | 963.64% | 1632.28% | 63952.5% | 1792.08% |
| Research & Development | 25.51M | 33.45M | 47.91M | 73.5M | 71.44M | 110.19M | 190.65M | 203.74M | 113.03M |
| R&D % of Revenue | 320.88% | 446.05% | 526.86% | 573.82% | 1002.67% | 5026.73% | 10591.56% | 101871.5% | 8694.46% |
| Other Operating Expenses | 24K | 68K | -4.12M | -80K | -71.45M | -110.19M | -199K | -2.29M | 0 |
| Operating Income | -19.73M▲ 0% | -29.51M▼ 49.6% | -43.71M▼ 48.1% | -67.44M▼ 54.3% | -76.56M▼ 13.5% | -129.12M▼ 68.6% | -219.22M▼ 69.8% | -331.45M▼ 51.2% | -135.03M▲ 59.3% |
| Operating Margin % | -248.15% | -393.51% | -480.74% | -526.57% | -1074.58% | -5890.37% | -12178.94% | -165724% | -10386.54% |
| Operating Income Growth % | -62.42% | -49.6% | -48.12% | -54.28% | -13.52% | -68.64% | -69.78% | -51.19% | 59.26% |
| EBITDA | -19.33M | -28.84M | -41.2M | -66.42M | -75.37M | -127.89M | -218.03M | -329.16M | -135.03M |
| EBITDA Margin % | -243.13% | -384.49% | -453.05% | -518.61% | -1057.81% | -5834.49% | -12112.78% | -164581.5% | -10386.54% |
| EBITDA Growth % | -62.52% | -49.19% | -42.86% | -61.24% | -13.47% | -69.69% | -70.48% | -50.97% | 58.98% |
| D&A (Non-Cash Add-back) | 399K | 676K | 2.52M | 1.02M | 1.2M | 1.23M | 1.19M | 2.29M | 0 |
| EBIT | -19.7M | -29.45M | -44.78M | -64.82M | -76.56M | -127.04M | -207.88M | 1.7B | 0 |
| Net Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | -19.92M | -2.55M | 0 |
| Interest Income | 0 | 0 | 5.72M | 10.82M | 5.22M | 16.11M | 11.92M | 10.94M | 7.55M |
| Interest Expense | 2.13M | 1.48M | 5.72M | 10.82M | 5.22M | 16.11M | 31.84M | 13.49M | -12.2M |
| Other Income/Expense | -2.1M | -1.41M | -6.79M | -8.19M | -5.2M | -16.11M | -20.5M | 2.02B | -5.03M |
| Pretax Income | -21.83M▲ 0% | -30.93M▼ 41.7% | -50.5M▼ 63.3% | -75.63M▼ 49.8% | -81.77M▼ 8.1% | -145.22M▼ 77.6% | -239.72M▼ 65.1% | 1.69B▲ 804.0% | -140.05M▼ 108.3% |
| Pretax Margin % | -274.59% | -412.33% | -555.39% | -590.52% | -1147.59% | -6625.14% | -13318% | 843787% | -10773.31% |
| Income Tax | 250K | 96K | 898K | 3K | 2K | 3K | 3K | 2K | 2K |
| Effective Tax Rate % | -1.15% | -0.31% | -1.78% | -0% | -0% | -0% | -0% | 0% | -0% |
| Net Income | -19.44M▲ 0% | -31.16M▼ 60.3% | -51.4M▼ 64.9% | -75.64M▼ 47.2% | -81.77M▼ 8.1% | -145.23M▼ 77.6% | -241.36M▼ 66.2% | 1.69B▲ 799.2% | -140.06M▼ 108.3% |
| Net Margin % | -244.55% | -415.51% | -565.27% | -590.54% | -1147.62% | -6625.27% | -13408.94% | 843786% | -10773.46% |
| Net Income Growth % | -135.12% | -60.29% | -64.94% | -47.15% | -8.11% | -77.61% | -66.2% | 799.19% | -108.3% |
| Net Income (Continuing) | -19.44M | -31.16M | -51.4M | -75.64M | -81.77M | -145.23M | -239.73M | 1.69B | -140.06M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 6.35M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.68▲ 0% | -1.15▼ 69.1% | -1.41▼ 22.6% | -2.99▼ 112.1% | -2.15▲ 28.1% | -3.62▼ 68.4% | -5.12▼ 41.4% | 116.58▲ 2377.0% | -9.04▼ 107.8% |
| EPS Growth % | -195.65% | -69.12% | -22.61% | -112.06% | 28.09% | -68.37% | -41.44% | 2376.95% | -107.75% |
| EPS (Basic) | -0.68 | -1.15 | -1.41 | -2.99 | -2.15 | -3.62 | -5.12 | 116.58 | -9.04 |
| Diluted Shares Outstanding | 28.79M | 27.08M | 36.55M | 25.26M | 38.01M | 40.11M | 47.13M | 14.48M | 15.49M |
| Basic Shares Outstanding | 28.79M | 27.08M | 36.55M | 25.26M | 38.01M | 40.11M | 47.13M | 14.48M | 15.49M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
INBX Balance Sheet
Inhibrx Biosciences, Inc. (INBX) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 15.44M | 5.66M | 15.56M | 132.17M | 139.11M | 280.49M | 295.36M | 160.4M | 132.83M |
| Cash & Short-Term Investments | 13.47M | 2.1M | 11.54M | 128.66M | 131.3M | 273.87M | 277.92M | 152.6M | 124.22M |
| Cash Only | 13.47M | 2.1M | 11.54M | 128.66M | 131.3M | 273.87M | 277.92M | 152.6M | 124.22M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 696K | 690K | 438K | 615K | 878K | 257K | 778K | 420K | 177K |
| Days Sales Outstanding | 31.95 | 33.58 | 17.58 | 17.53 | 44.98 | 42.79 | 157.76 | 766.5 | 49.7 |
| Inventory | 999K | 2.31M | 3.21M | -129.28M | -878K | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | 14.29 | 25.21 | 24.43 | - | - | - | - | - | - |
| Other Current Assets | 276K | 553K | 376K | 132.17M | 7.81M | 181K | 728K | 816K | 238K |
| Total Non-Current Assets | 1.8M | 4.33M | 10.93M | 11.57M | 11.34M | 10.38M | 12.54M | 20.37M | 13.65M |
| Property, Plant & Equipment | 1.8M | 2.59M | 10.68M | 11.32M | 9.49M | 7.22M | 9.37M | 13.54M | 9.27M |
| Fixed Asset Turnover | 4.40x | 2.89x | 0.85x | 1.13x | 0.75x | 0.30x | 0.19x | 0.01x | 0.14x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 1.73M | 245K | 245K | 1.85M | 3.16M | 3.16M | 6.83M | 4.38M |
| Total Assets | 17.25M▲ 0% | 9.98M▼ 42.1% | 26.49M▲ 165.3% | 143.74M▲ 442.6% | 150.45M▲ 4.7% | 290.88M▲ 93.3% | 307.89M▲ 5.9% | 180.77M▼ 41.3% | 146.48M▼ 19.0% |
| Asset Turnover | 0.46x | 0.75x | 0.34x | 0.09x | 0.05x | 0.01x | 0.01x | 0.00x | 0.01x |
| Asset Growth % | -18.93% | -42.11% | 165.31% | 442.64% | 4.67% | 93.34% | 5.85% | -41.29% | -18.97% |
| Total Current Liabilities | 8.92M | 16.18M | 20.57M | 31.4M | 22.45M | 27.58M | 56.31M | 40.73M | 33.8M |
| Accounts Payable | 775K | 6.53M | 3.12M | 13.46M | 9.13M | 8.33M | 10.95M | 9.24M | 5.94M |
| Days Payables Outstanding | 11.09 | 71.25 | 23.73 | 66.84 | 1.24K | 27.58 | 3.36K | 1.48K | - |
| Short-Term Debt | 5.17M | 5.93M | 4.67M | 1.5M | 1.67M | 1.86M | 0 | 1.59M | 2.33M |
| Deferred Revenue (Current) | 2.61M | 1.63M | 7.94M | 3.08M | 2.03M | 166K | 0 | 0 | 0 |
| Other Current Liabilities | 372K | 2.09M | 4.85M | 13.36M | 9.62M | 13.85M | 6.51M | 7.73M | 18.08M |
| Current Ratio | 1.73x | 0.35x | 0.76x | 4.21x | 6.20x | 10.17x | 5.25x | 3.94x | 3.93x |
| Quick Ratio | 1.62x | 0.21x | 0.60x | 8.33x | 6.23x | 10.17x | 5.25x | 3.94x | 3.93x |
| Cash Conversion Cycle | 35.16 | -12.45 | 18.28 | - | - | - | - | - | - |
| Total Non-Current Liabilities | 30.75M | 51.45M | 99.49M | 36.87M | 75.61M | 205.24M | 208.08M | 6.45M | 104.69M |
| Long-Term Debt | 9.49M | 3.56M | 37.06M | 35.95M | 70.47M | 202.07M | 206.97M | 0 | 100.56M |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 3.17M | 1.11M | 6.45M | 4.13M |
| Deferred Tax Liabilities | 0 | 0 | -6.7M | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 21.25M | 47.88M | 68.12M | 180K | 5.03M | 0 | 0 | 0 | 0 |
| Total Liabilities | 39.67M | 67.63M | 120.06M | 68.27M | 98.07M | 232.82M | 264.39M | 47.18M | 138.49M |
| Total Debt | 14.66M | 9.49M | 41.73M | 37.45M | 72.14M | 207.1M | 210.14M | 8.05M | 107.01M |
| Net Debt | 1.19M | 7.39M | 30.19M | -91.21M | -59.16M | -66.76M | -67.78M | -144.55M | -17.21M |
| Debt / Equity | - | - | - | 0.50x | 1.38x | 3.57x | 4.83x | 0.06x | 13.39x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -9.28x | -19.94x | -7.64x | -6.24x | -14.68x | -8.02x | -6.89x | -24.57x | - |
| Total Equity | -22.42M▲ 0% | -57.64M▼ 157.1% | -93.57M▼ 62.3% | 75.47M▲ 180.7% | 52.38M▼ 30.6% | 58.06M▲ 10.8% | 43.5M▼ 25.1% | 133.58M▲ 207.1% | 7.99M▼ 94.0% |
| Equity Growth % | -1909.52% | -157.11% | -62.32% | 180.66% | -30.59% | 10.83% | -25.07% | 207.07% | -94.02% |
| Book Value per Share | -0.78 | -2.13 | -2.56 | 2.99 | 1.38 | 1.45 | 0.92 | 9.23 | 0.52 |
| Total Shareholders' Equity | -28.77M | -57.64M | -93.57M | 75.47M | 52.38M | 58.06M | 43.5M | 133.58M | 7.99M |
| Common Stock | 0 | 3K | 2K | 4K | 4K | 4K | 5K | 1K | 1K |
| Retained Earnings | -28.77M | -17.86M | -69.25M | -145.38M | -227.15M | -372.37M | -613.73M | -106.13M | -246.19M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -1.03M | -1.71M | -59.51M | -143.74M | -150.45M | 0 | 0 | 0 | 0 |
| Minority Interest | 6.35M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
INBX Cash Flow Statement
Inhibrx Biosciences, Inc. (INBX) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -18.75M | -23.09M | -32.08M | -47.97M | -80.32M | -115.3M | -193.31M | -194.41M | -129.79M |
| Operating CF Margin % | -235.87% | -307.89% | -352.79% | -374.52% | -1127.34% | -5260.08% | -10739.39% | -97204.5% | -9984.15% |
| Operating CF Growth % | -3.56% | -23.14% | -38.92% | -49.53% | -67.45% | -43.55% | -67.66% | -0.57% | 33.24% |
| Net Income | -22.08M | -31.02M | -51.4M | -76.12M | -81.77M | -145.23M | -239.73M | 1.69B | -140.06M |
| Depreciation & Amortization | 399K | 676K | 1.16M | 1.02M | 1.2M | 1.23M | 1.19M | 2.29M | 2.48M |
| Stock-Based Compensation | 1.18M | 2.48M | 3.97M | 5.02M | 15.05M | 20.45M | 24.85M | 58.52M | 11.14M |
| Deferred Taxes | 0 | 0 | 1.08M | -2.14M | -9K | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 746K | 522K | 9.61M | 11.56M | 2.73M | 5.09M | 5.03M | -1.99B | -3.36M |
| Working Capital Changes | 999K | 4.25M | 3.48M | 12.69M | -17.52M | 3.16M | 15.35M | 52.05M | 0 |
| Change in Receivables | -140K | -550K | 491K | 117K | -167K | 130K | -521K | 381K | 200K |
| Change in Inventory | 1.09M | -672K | -2.47M | 7.76M | -11.03M | 0 | 0 | 0 | 0 |
| Change in Payables | 608K | 4.91M | -3.47M | 10.43M | -4.64M | -705K | 2.11M | 17.9M | -3.3M |
| Cash from Investing | -1.34M | -1.43M | -1.81M | -1.36M | -809K | -686K | -4.59M | -2.6M | -28K |
| Capital Expenditures | -1.34M | -1.43M | -1.81M | -1.36M | -864K | -686K | -4.59M | -2.6M | -31K |
| CapEx % of Revenue | 16.86% | 19.05% | 19.91% | 10.65% | 12.13% | 31.3% | 255.17% | 1298.5% | 2.38% |
| Acquisitions | 0 | 0 | 0 | 0 | 55K | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3K |
| Cash from Financing | 13.54M | 13.15M | 43.33M | 166.46M | 83.77M | 258.55M | 201.96M | 71.68M | 101.45M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 0 | 0 | 0 | 0 | 0 | 1000K | 1000K | 1000K | 0 |
| Dividends Paid | -1.38M | -828K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 14.91M | 13.98M | 43.33M | 166.46M | 83.77M | 128.81M | 0 | 0 | 101.45M |
| Net Change in Cash | -6.55M▲ 0% | -11.37M▼ 73.4% | 9.44M▲ 183.0% | 117.12M▲ 1141.1% | 2.64M▼ 97.7% | 142.56M▲ 5306.3% | 4.06M▼ 97.2% | -125.33M▼ 3187.7% | -28.38M▲ 77.4% |
| Free Cash Flow | -20.09M▲ 0% | -24.52M▼ 22.0% | -33.89M▼ 38.2% | -49.33M▼ 45.6% | -81.19M▼ 64.6% | -115.99M▼ 42.9% | -197.9M▼ 70.6% | -197.01M▲ 0.5% | -129.82M▲ 34.1% |
| FCF Margin % | -252.73% | -326.95% | -372.69% | -385.17% | -1139.47% | -5291.38% | -10994.56% | -98503% | -9986.54% |
| FCF Growth % | -9.65% | -22.04% | -38.2% | -45.57% | -64.57% | -42.86% | -70.62% | 0.45% | 34.1% |
| FCF per Share | -0.70 | -0.91 | -0.93 | -1.95 | -2.14 | -2.89 | -4.20 | -13.61 | -8.38 |
| FCF Conversion (FCF/Net Income) | 0.96x | 0.74x | 0.62x | 0.63x | 0.98x | 0.79x | 0.80x | -0.12x | 0.93x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 26.72M | 11.51M | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 4K | 3K | 2K | 0 |
INBX Key Ratios
Inhibrx Biosciences, Inc. (INBX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -667.39% | - | - | - | -100.22% | -127.91% | -263% | -475.31% | 1905.92% | -197.85% |
| Return on Invested Capital (ROIC) | -6901.14% | - | - | - | - | - | - | - | - | - |
| Gross Margin | -154.87% | -220.88% | -346.05% | -426.86% | -473.82% | 62.27% | -4926.73% | 33.83% | -1042.5% | - |
| Net Margin | -124.03% | -244.55% | -415.51% | -565.27% | -590.54% | -1147.62% | -6625.27% | -13408.94% | 843786% | -10773.46% |
| Debt / Equity | 15.27x | - | - | - | 0.50x | 1.38x | 3.57x | 4.83x | 0.06x | 13.39x |
| Interest Coverage | - | -9.28x | -19.94x | -7.64x | -6.24x | -14.68x | -8.02x | -6.89x | -24.57x | - |
| FCF Conversion | 2.19x | 0.96x | 0.74x | 0.62x | 0.63x | 0.98x | 0.79x | 0.80x | -0.12x | 0.93x |
| Revenue Growth | - | 19.24% | -5.66% | 21.24% | 40.86% | -44.37% | -69.24% | -17.88% | -88.89% | 550% |
INBX SEC Filings & Documents
Inhibrx Biosciences, Inc. (INBX) SEC filings — annual & quarterly reports (10-K, 10-Q)
INBX Frequently Asked Questions
Inhibrx Biosciences, Inc. (INBX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Inhibrx Biosciences, Inc. (INBX) reported $1.3M in revenue for fiscal year 2025. This represents a 81% decrease from $6.7M in 2016.
Inhibrx Biosciences, Inc. (INBX) grew revenue by 550.0% over the past year. This is strong growth.
Inhibrx Biosciences, Inc. (INBX) reported a net loss of $140.1M for fiscal year 2025.
Dividend & Returns
Inhibrx Biosciences, Inc. (INBX) has a return on equity (ROE) of -197.8%. Negative ROE indicates the company is unprofitable.
Inhibrx Biosciences, Inc. (INBX) had negative free cash flow of $129.8M in fiscal year 2025, likely due to heavy capital investments.
Explore More INBX
Inhibrx Biosciences, Inc. (INBX) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates